CIC::DUX4 Sarcoma With Preferentially Expressed Antigen in Melanoma (PRAME) Immunopositivity

CIC::DUX4 肉瘤伴黑色素瘤优先表达抗原 (PRAME) 免疫阳性

阅读:1

Abstract

CIC-rearranged sarcomas are rare, high-grade, undifferentiated, small round cell sarcomas of bone and soft tissue classified by gene fusions involving the CIC gene with other gene partners, most commonly the DUX4 gene. These tumors tend to affect a wide age range, with a predilection for adult males, with the most common anatomical location being the deep soft tissues of the limbs or trunk. CIC-rearranged sarcomas have proven not only to be challenging to diagnose but also to treat due to their high resistance to conventional therapies. Preferentially expressed antigen in melanoma (PRAME) is an immunohistochemical stain that was developed primarily for the diagnosis of melanoma and has been shown to also be expressed in other epithelial and mesenchymal tumors. To date, PRAME immunopositivity has not been reported in CIC-rearranged sarcomas. Here, we report a 51-year-old male with a large gluteal undifferentiated small round cell sarcoma and bilateral lung metastases, whereby RNA sequencing confirmed the tumor as CIC::DUX4 sarcoma. Interestingly, the sarcoma demonstrated very strong PRAME immunohistochemical positivity, a diagnostic finding that has not yet been reported on CIC::DUX4 sarcomas and has potential use as a beneficial tool in the workup of a diagnostically challenging disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。